Warning: The NCBI web site requires JavaScript to function. more...
Control of hyperuricemia in subjects with refractory gout, and induction of antibody against poly(ethylene glycol) (PEG), in a phase I trial of subcutaneous PEGylated urate oxidase.
Ganson NJ, Kelly SJ, Scarlett E, Sundy JS, Hershfield MS.
Arthritis Res Ther. 2006;8(1):R12.
Related citations
Pharmacokinetics and pharmacodynamics of intravenous PEGylated recombinant mammalian urate oxidase in patients with refractory gout.
Sundy JS, Ganson NJ, Kelly SJ, Scarlett EL, Rehrig CD, Huang W, Hershfield MS.
Arthritis Rheum. 2007 Mar;56(3):1021-8. Erratum in: Arthritis Rheum. 2007 Apr;56(4):1370.
Use of polyethylene glycol-modified uricase (PEG-uricase) to treat hyperuricemia in a patient with non-Hodgkin lymphoma.
Chua CC, Greenberg ML, Viau AT, Nucci M, Brenckman WD Jr, Hershfield MS.
Ann Intern Med. 1988 Jul 15;109(2):114-7.
PEG-uricase in the management of treatment-resistant gout and hyperuricemia.
Sherman MR, Saifer MG, Perez-Ruiz F.
Adv Drug Deliv Rev. 2008 Jan 3;60(1):59-68. Epub 2007 Aug 14. Review.
Reduction of plasma urate levels following treatment with multiple doses of pegloticase (polyethylene glycol-conjugated uricase) in patients with treatment-failure gout: results of a phase II randomized study.
Sundy JS, Becker MA, Baraf HS, Barkhuizen A, Moreland LW, Huang W, Waltrip RW 2nd, Maroli AN, Horowitz Z; Pegloticase Phase 2 Study Investigators.
Arthritis Rheum. 2008 Sep;58(9):2882-91.
Uricase formulated with polyethylene glycol (uricase-PEG 20): biochemical rationale and preclinical studies.
Bomalaski JS, Holtsberg FW, Ensor CM, Clark MA.
J Rheumatol. 2002 Sep;29(9):1942-9.
Diabetes insipidus in uricase-deficient mice: a model for evaluating therapy with poly(ethylene glycol)-modified uricase.
Kelly SJ, Delnomdedieu M, Oliverio MI, Williams LD, Saifer MG, Sherman MR, Coffman TM, Johnson GA, Hershfield MS.
J Am Soc Nephrol. 2001 May;12(5):1001-9.
A new practical system for evaluating the pharmacological properties of uricase as a potential drug for hyperuricemia.
Feng J, Li X, Yang X, Zhang C, Yuan Y, Pu J, Zhao Y, Xie Y, Yuan H, Bu Y, Liao F.
Arch Pharm Res. 2010 Nov;33(11):1761-9. Epub 2010 Nov 30.
Induction of tolerance in mice by uricase and monomethoxypolyethylene glycol-modified uricase.
Savoca KV, Davis FF, Palczuk NC.
Int Arch Allergy Appl Immunol. 1984;75(1):58-67.
Population pharmacokinetic and pharmacodynamic analysis of pegloticase in subjects with hyperuricemia and treatment-failure gout.
Yue CS, Huang W, Alton M, Maroli AN, Waltrip RW, Wright D, Marco MD.
J Clin Pharmacol. 2008 Jun;48(6):708-18. Epub 2008 Apr 16.
Pegloticase, a polyethylene glycol conjugate of uricase for the potential intravenous treatment of gout.
Biggers K, Scheinfeld N.
Curr Opin Investig Drugs. 2008 Apr;9(4):422-9. Review.
Efficacy and tolerability of pegloticase for the treatment of chronic gout in patients refractory to conventional treatment: two randomized controlled trials.
Sundy JS, Baraf HS, Yood RA, Edwards NL, Gutierrez-Urena SR, Treadwell EL, Vázquez-Mellado J, White WB, Lipsky PE, Horowitz Z, Huang W, Maroli AN, Waltrip RW 2nd, Hamburger SA, Becker MA.
JAMA. 2011 Aug 17;306(7):711-20.
Serum uric acid-lowering therapies: where are we heading in management of hyperuricemia and the potential role of uricase.
Bomalaski JS, Clark MA.
Curr Rheumatol Rep. 2004 Jun;6(3):240-7. Review.
Studies on antigenicity of the polyethylene glycol (PEG)-modified uricase.
Tsuji J, Hirose K, Kasahara E, Naitoh M, Yamamoto I.
Int J Immunopharmacol. 1985;7(5):725-30.
Febuxostat, a novel nonpurine selective inhibitor of xanthine oxidase: a twenty-eight-day, multicenter, phase II, randomized, double-blind, placebo-controlled, dose-response clinical trial examining safety and efficacy in patients with gout.
Becker MA, Schumacher HR Jr, Wortmann RL, MacDonald PA, Palo WA, Eustace D, Vernillet L, Joseph-Ridge N.
Arthritis Rheum. 2005 Mar;52(3):916-23.
Treating gout with pegloticase, a PEGylated urate oxidase, provides insight into the importance of uric acid as an antioxidant in vivo.
Hershfield MS, Roberts LJ 2nd, Ganson NJ, Kelly SJ, Santisteban I, Scarlett E, Jaggers D, Sundy JS.
Proc Natl Acad Sci U S A. 2010 Aug 10;107(32):14351-6. Epub 2010 Jul 26.
Pegloticase: in treatment-refractory chronic gout.
Lyseng-Williamson KA.
Drugs. 2011 Nov 12;71(16):2179-92. doi: 10.2165/11202830-000000000-00000. Review.
Urate-oxidase for the treatment of tophaceous gout in heart transplant recipients. A report of three cases.
Rozenberg S, Roche B, Dorent R, Koeger AC, Borget C, Wrona N, Bourgeois P.
Rev Rhum Engl Ed. 1995 May;62(5):392-4.
Efficacy and safety of rasburicase (recombinant urate oxidase) for the prevention and treatment of hyperuricemia during induction chemotherapy of aggressive non-Hodgkin's lymphoma: results of the GRAAL1 (Groupe d'Etude des Lymphomes de l'Adulte Trial on Rasburicase Activity in Adult Lymphoma) study.
Coiffier B, Mounier N, Bologna S, Fermé C, Tilly H, Sonet A, Christian B, Casasnovas O, Jourdan E, Belhadj K, Herbrecht R; Groupe d'Etude des Lymphomes de l'Adulte Trial on Rasburicase Activity in Adult Lymphoma.
J Clin Oncol. 2003 Dec 1;21(23):4402-6. Epub 2003 Oct 27.
Use of the uricase-inhibited rat as an animal model in toxicology.
Stavric B, Nera EA.
Clin Toxicol. 1978;13(1):47-74. Review.
Filter your results:
Your browsing activity is empty.
Activity recording is turned off.
Turn recording back on